PL441816A1 - Pharmaceutical composition containing a GGT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer - Google Patents

Pharmaceutical composition containing a GGT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer

Info

Publication number
PL441816A1
PL441816A1 PL441816A PL44181622A PL441816A1 PL 441816 A1 PL441816 A1 PL 441816A1 PL 441816 A PL441816 A PL 441816A PL 44181622 A PL44181622 A PL 44181622A PL 441816 A1 PL441816 A1 PL 441816A1
Authority
PL
Poland
Prior art keywords
cysltr1
cancer
treatment
pharmaceutical composition
composition containing
Prior art date
Application number
PL441816A
Other languages
Polish (pl)
Inventor
Katarzyna Ewa SOBIERAJSKA
Wojciech Michał CISZEWSKI
Original Assignee
Uniwersytet Medyczny w Łodzi
Sobierajska Katarzyna Ewa
Ciszewski Wojciech Michał
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny w Łodzi, Sobierajska Katarzyna Ewa, Ciszewski Wojciech Michał filed Critical Uniwersytet Medyczny w Łodzi
Priority to PL441816A priority Critical patent/PL441816A1/en
Priority to PCT/IB2023/057151 priority patent/WO2024018334A1/en
Publication of PL441816A1 publication Critical patent/PL441816A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna zawierająca inhibitor białka GTT1 i antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu.The subject of the application is a pharmaceutical composition containing a GTT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer.

PL441816A 2022-07-22 2022-07-22 Pharmaceutical composition containing a GGT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer PL441816A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL441816A PL441816A1 (en) 2022-07-22 2022-07-22 Pharmaceutical composition containing a GGT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer
PCT/IB2023/057151 WO2024018334A1 (en) 2022-07-22 2023-07-12 Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441816A PL441816A1 (en) 2022-07-22 2022-07-22 Pharmaceutical composition containing a GGT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer

Publications (1)

Publication Number Publication Date
PL441816A1 true PL441816A1 (en) 2024-01-29

Family

ID=87569894

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441816A PL441816A1 (en) 2022-07-22 2022-07-22 Pharmaceutical composition containing a GGT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer

Country Status (2)

Country Link
PL (1) PL441816A1 (en)
WO (1) WO2024018334A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
CN108135875B (en) * 2015-07-31 2021-12-31 约翰霍普金斯大学 Methods and compositions for treating metabolic reprogramming disorders

Also Published As

Publication number Publication date
WO2024018334A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
CY1125065T1 (en) MCL-1 INHIBITORS
CR8932A (en) HER2 ANTIBODY COMPOSITION
PA8564901A1 (en) PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE CHOLESTERILE ESTERES TRANSFER PROTEIN
NO20056131L (en) A pharmaceutical composition comprising a P2X7 receptor antagonist and a tumor necrosis factor alpha
CL2008002886A1 (en) Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it.
DK1368060T3 (en) HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease
ECSP21038390A (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE PREPARATION OF COMPOUNDS AND THEIR USE AS INHIBITORS OF KINASE ATR
CL2004001621A1 (en) USE OF A COMBINED THERAPY OF METOTREXATE AND OTHER ACTIVE AGENTS FOR THE TREATMENT OF Rheumatoid ARTHRITIS.
CY1110271T1 (en) HYDRAULIC PHARMACEUTICAL PHARMACEUTICAL FORMS OF PROTEINS
CL2011000230A1 (en) Isolated human monoclonal antibody that binds to the tissue factor pathway inhibitor (tfpi); pharmaceutical composition that includes it; use to treat acquired or genetic deficiencies of coagulation, or to shorten bleeding time.
BRPI0507856A (en) pharmaceutical composition and process for preparing the abeta antibody
FR2848116B1 (en) COSMETIC COMPOSITION COMPRISING A METALLO-PROTEINASE INHIBITOR AND A LIPOPEPTIDE
EA202191806A1 (en) ANTIBODY AGAINST HUMAN IL-4RA AND ITS APPLICATION
BR112022014058A2 (en) Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (RMS)
PE20231376A1 (en) ANTIBODIES AGAINST SARS-COV-2 AND METHODS AND SELECTION AND USE THEREOF
EA202091318A1 (en) A PREPARATION CONTAINING GROUP B ADENOVIRUS
CY1107203T1 (en) Use of IL-18 inhibitors for the treatment and / or prevention of cardiac disease
CL2021002662S1 (en) Personal hygiene device. (divisional request 202002626)
MA52712A (en) ANTIBODY ANTI- (POLY-GA) DIRECTED AGAINST DIPEPTIDIC REPETITIONS (DPR) OF HUMAN ORIGIN
PL441816A1 (en) Pharmaceutical composition containing a GGT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer
CL2023002446A1 (en) enzyme inhibitors
ATE534380T1 (en) GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISEASES
PL441358A1 (en) Inhibitor of ABCC1 transporter activity for use in treatment of invasive stages of cancer by inhibiting its invasive capacity, and pharmaceutical composition containing such an inhibitor
FR3109297A1 (en) &#34;New non-protein furin inhibitor&#34;
PL442316A1 (en) Pharmaceutical composition for topical use and its use in the treatment of hemangiomas in children